The medical cannabis industry has long recognised the importance of clinical evidence.
Now, another significant milestone has been reached.
Exilby® (VER-01), a prescription medicine developed from a standardised full-spectrum cannabis extract, has received market authorisation in Germany and Austria for the treatment of chronic lower back pain with a neuropathic component. Following more than a decade of research and development, the medicine is the first cannabis-derived therapy in Europe to receive approval for this indication after completing large-scale Phase 3 clinical trials. UK approval is anticipated later this year, subject to regulatory review.
While one medicine will not redefine the sector overnight, the approval represents something much bigger.
It demonstrates how cannabis-based medicines are increasingly being evaluated through the same scientific and regulatory standards expected of other prescription medicines.
For the wider medical cannabis industry, this is an important shift.
Key Takeaways
- Exilby® has received market authorisation in Germany and Austria for chronic lower back pain with a neuropathic component.
- The medicine is supported by more than a decade of development and two Phase 3 clinical trials involving over 1,200 patients.
- The approval reflects growing investment in evidence-based medical cannabis.
- Clinical trials and real-world evidence will continue to shape the future of cannabinoid medicines.
- Scientific evidence remains essential to building confidence among regulators, clinicians and healthcare systems.
A Milestone for Cannabis-Based Medicines
Medical cannabis has evolved significantly over the past decade.
Early discussions often focused on access, regulation and stigma.
Today, the conversation is increasingly centred on evidence.
Exilby's approval reflects this evolution.
Rather than relying on observational data alone, the medicine has progressed through the traditional pharmaceutical development pathway, including large-scale Phase 3 clinical trials before receiving market authorisation for a specific indication.
This is an important milestone not only for one product but for the wider acceptance of cannabis-based medicines within modern healthcare.
Why Phase 3 Clinical Trials Matter
Randomised controlled trials remain the cornerstone of evidence-based medicine.
Phase 3 studies are designed to evaluate whether a treatment demonstrates meaningful clinical benefit while maintaining an acceptable safety profile in larger patient populations.
In the case of Exilby®, more than 1,200 patients participated across two Phase 3 studies evaluating chronic lower back pain with a neuropathic component. According to the reported findings, the medicine demonstrated significant pain reduction, was generally well tolerated and showed no evidence of dependence within the clinical programme.
For healthcare professionals, this level of evidence provides an important foundation for clinical decision-making.
Chronic Pain Remains a Major Unmet Need
Chronic pain continues to affect millions of people across Europe.
Despite a range of available treatments, many patients continue to experience inadequate symptom control or encounter tolerability challenges with existing therapies.
Neuropathic pain, in particular, remains difficult to manage and often requires multiple treatment approaches.
The continued development of cannabis-based medicines for chronic pain reflects growing recognition that additional therapeutic options may be needed for some patients.
Evidence Is Changing the Medical Cannabis Conversation
One of the biggest barriers facing medical cannabis has been the perception that evidence has not kept pace with clinical interest.
That landscape is changing.
Alongside randomised controlled trials, increasing volumes of real-world evidence are helping researchers and clinicians better understand how cannabis-based medicines perform in routine clinical practice.
Together, these complementary sources of evidence are creating a stronger foundation for future prescribing, regulatory decision-making and healthcare policy.
The future of medical cannabis will not be shaped by anecdote alone. It will be shaped by data.
What Does This Mean for the UK?
Exilby® has not yet received market authorisation in the UK, although approval is anticipated later this year, subject to regulatory review. Until then, access to cannabis-based medicines in the UK continues through existing prescribing pathways.
Regardless of the regulatory timeline, the significance extends beyond one product.
Every successful clinical programme strengthens the wider evidence base supporting cannabinoid medicines. Every published study contributes to clinical understanding. Every regulatory approval helps build confidence among clinicians, healthcare providers and policymakers.
The Role of Real-World Evidence
Clinical trials answer important questions under controlled conditions.
Real-world evidence helps answer equally important questions about how treatments perform across broader patient populations and routine clinical practice.
Together, they provide a more complete understanding of effectiveness, safety and patient outcomes.
As the medical cannabis sector continues to mature, combining high-quality clinical trials with robust real-world data will be essential to informing future prescribing decisions and supporting evidence-led healthcare.
What This Means for the Industry
For manufacturers, distributors, clinicians and healthcare providers, Exilby's approval signals an important direction of travel.
The future of medical cannabis will increasingly depend on:
- High-quality clinical research
- Regulatory standards
- Product consistency
- Evidence-led prescribing
- Long-term safety monitoring
- Real-world patient outcomes
The organisations that invest in evidence will be best placed to support the continued integration of cannabis-based medicines into mainstream healthcare.
Frequently Asked Questions
What is Exilby®?
Exilby® (VER-01) is a prescription medicine developed from a standardised full-spectrum cannabis extract. It has received market authorisation in Germany and Austria for chronic lower back pain with a neuropathic component.
Why is Exilby's approval significant?
It represents the first European approval of a cannabis-derived medicine for this indication following large-scale Phase 3 clinical trials, demonstrating the growing role of evidence-based medicine in the sector.
Is Exilby available in the UK?
Not currently. UK approval is anticipated later this year, subject to regulatory review.
Why are clinical trials important in medical cannabis?
Clinical trials help establish whether treatments are safe and effective. Alongside real-world evidence, they provide the scientific foundation needed to support prescribing, regulation and future research.
Conclusion
Exilby's approval is more than the launch of a new medicine.
It represents another step in the evolution of medical cannabis from an emerging therapeutic area to one increasingly defined by scientific evidence, regulatory rigour and clinical confidence.
At Cantourage, we believe the future of medical cannabis will be built on high-quality evidence. Clinical trials, real-world outcomes and continued research all have a role to play in improving patient care and supporting informed prescribing decisions.
As the evidence base continues to grow, so too does the opportunity to integrate cannabis-based medicines into modern healthcare with the same scientific standards expected of any other prescription medicine.
